Connect with us

Hi, what are you looking for?

Jewish Business News


Israel’s MeMed New COVID-19 Severity Test Approved In Europe

MeMed is an Israeli medtech company. MeMed has received the CE Mark in Europe for its new disease management solution, MeMed COVID-19 Severity.

The CE marking in Europe indicates that a product has been assessed by the manufacturer and deemed to meet EU safety, health and environmental protection requirements. This certification is a prerequisite for the marketing of any product manufactured outside of the EU if it is to be permitted for sale within the EU.

MeMed is a medtech and bio-convergence company that has developed innovative diagnostic host immune response testing methods that address complex clinical dilemmas and improve patient outcomes. This includes testing for Covid-19.

Just when you thought that the world had reopened after the long Covid nightmare, things seem to have backslid now into another global shutdown. This is because the Delta variant has been proven to be much more virulent with a higher rate of morbidity than the original Coronavirus. Even the vaccinated can be affected, but at least the data shows that those vaccinated might get sick, but not so ill that it would be life-threatening.

So now countries like Israel are re-imposing Covid rules such as requiring masks in indoor public spaces. Israel is also requiring that all international travelers get tested both before and after their flights. So any and all new Covid tests that can be faster and more efficient are welcome news.

But the new MeMed test is different. This test checks to see the probability that someone might become seriously ill.

MeMed COVID-19 Severity is a host response technology that measures multiple proteins from a serum sample and applies machine learning to stratify the risk that a patient with COVID-19 disease is likely to experience severe outcomes.

The test runs in 15 minutes on the company’s point-of-need platform, MeMed Key, and aims to help physicians identify who may benefit from escalated care and who may be safely discharged from the hospital and instructed to self-isolate at home.

Eran Eden, MeMed’s co-founder and CEO, said: “I am delighted that we are now able to commercialize a pioneering solution to help identify COVID-19 patients at risk of severe outcomes, empowering physicians to manage what is increasingly likely to become an endemic situation. MeMed COVID-19 Severity is also relevant for authorities contemplating preparedness for future pandemics.
It is another exciting step in the company’s long-term vision of harnessing the power of the host-immune response in order to transform the way infections are detected and managed.”

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.



You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...


The contract signed between the Israeli government and Pfizer shows clearly and unequivocally that this is a clinical study on humans - The agreement...


After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...


Now Platika joins and elite club of $10 billion plus Israeli firms.